| 0.4084 -0.004 (-0.9%) | 08-18 14:05 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.53 |
1-year : | 0.62 |
| Resists | First : | 0.45 |
Second : | 0.53 |
| Pivot price | 0.41  |
|||
| Supports | First : | 0.36 |
Second : | 0.31 |
| MAs | MA(5) : | 0.41 |
MA(20) : | 0.4 |
| MA(100) : | 0.5 |
MA(250) : | 0.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 60 |
D(3) : | 67.3 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 2.57 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HKPD ] has closed above bottom band by 33.9%. Bollinger Bands are 76% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.44 - 0.44 | 0.44 - 0.44 |
| Low: | 0.39 - 0.39 | 0.39 - 0.4 |
| Close: | 0.41 - 0.41 | 0.41 - 0.42 |
Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.
Mon, 20 Jul 2026
Chenyu Andy Liang Net Worth (2026) - GuruFocus
Fri, 17 Jul 2026
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period - The Manila Times
Thu, 16 Jul 2026
Cellyan Biotechnology granted Nasdaq compliance extension; shares surge - MSN
Thu, 16 Jul 2026
12 Industrials Stocks Moving In Thursday's After-Market Session - Benzinga
Thu, 16 Jul 2026
Cellyan Biotechnology gets 180-day extension for Nasdaq compliance - Investing.com
Fri, 22 May 2026
Cellyan Biotechnology Faces Resistance at $0.57 After Recent Decline - Seasonality Effect - po-news-eg.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Distribution
|
|
| Shares Out | 16 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 33.1 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 179 (K) |
| Shares Short P.Month | 208 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | -8.5 % |
| Operating Margin | -19.2 % |
| Return on Assets (ttm) | -5.6 % |
| Return on Equity (ttm) | -15.6 % |
| Qtrly Rev. Growth | -31.8 % |
| Gross Profit (p.s.) | 0.08 |
| Sales Per Share | 0.82 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -6.81 |
| PEG Ratio | 0 |
| Price to Book value | 0.86 |
| Price to Sales | 0.49 |
| Price to Cash Flow | -8.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|